Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...

Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating on January 15.Stay Ahead of the ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...